AMEFX
Price
$24.22
Change
-$0.53 (-2.14%)
Updated
Dec 18 closing price
RIDGX
Price
$24.26
Change
-$0.53 (-2.14%)
Updated
Dec 18 closing price
Ad is loading...

AMEFX vs RIDGX

Header iconAMEFX vs RIDGX Comparison
Open Charts AMEFX vs RIDGXBanner chart's image
American Funds Income Fund of Amer F2
Price$24.22
Change-$0.53 (-2.14%)
VolumeN/A
CapitalizationN/A
American Funds Income Fund of Amer R6
Price$24.26
Change-$0.53 (-2.14%)
VolumeN/A
CapitalizationN/A
AMEFX vs RIDGX Comparison Chart
Loading...
View a ticker or compare two or three
VS
AMEFX vs. RIDGX commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMEFX is a Buy and RIDGX is a Buy.

FUNDAMENTALS
Fundamentals
AMEFX (126B) and RIDGX (126B) have equal amount of cash in the bank . RIDGX (3.83) and AMEFX (3.73) have matching dividends . AMEFX was incepted earlier than RIDGX: AMEFX (16 years) vs RIDGX (16 years). AMEFX (40.00) and RIDGX (40.00) have comparable annual turnover. AMEFX (250) and RIDGX (250) have matching initial minimum investment requirements. RIDGX (10.95) and AMEFX (10.88) have marching annual gain over last year. RIDGX (21.47) and AMEFX (21.04) have equivalent 5 years return.
AMEFXRIDGXAMEFX / RIDGX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence16 years16 years-
Gain YTD9.5089.57799%
Front LoadN/AN/A-
Min. Initial Investment250250100%
Min. Initial Investment IRAN/AN/A-
Net Assets126B126B100%
Annual Yield % from dividends3.733.8397%
Returns for 1 year10.8810.9599%
Returns for 3 years6.576.7897%
Returns for 5 years21.0421.4798%
Returns for 10 years33.7634.4698%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MLTX56.303.32
+6.27%
MoonLake Immunotherapeutics
CVKD11.450.45
+4.09%
Cadrenal Therapeutics Inc
CMPX1.530.04
+2.68%
Compass Therapeutics
WAT373.72-0.29
-0.08%
Waters Corp
PSTX9.50-0.01
-0.11%
Poseida Therapeutics